The
glycopeptide antibiotics vancomycin and
teicoplanin have similar mechanisms of action on bacterial cell wall synthesis. Their spectra of activity are limited to Gram-positive bacteria, with the degree of bactericidal activity depending on the species of micro-organism. Staphylococcus aureus, Staphylococcus epidermis, enterococci and Clostridium difficile are generally sensitive, including methicillin-resistant strains of S. aureus and S. epidermidis.
Glycopeptide resistance has recently emerged in staphylococci and enterococci.
Vancomycin has a shorter half-life than
teicoplanin and requires multiple dosing to maintain adequate serum levels. It can only be given by prolonged
intravenous infusion over 1 h. In contrast, the pharmacokinetics of
teicoplanin allow for once-daily dosing, either by rapid
intravenous infusion or by the intramuscular route. The latter offers reliable absorption for patients with limited venous access and is also of benefit for out-patient
therapy.
Teicoplanin is a safer
drug than
vancomycin. It is associated with a lower incidence of nephrotoxicity or
ototoxicity. Compared to
vancomycin, the availability of the intramuscular route and the absence of a requirement for routine serum monitoring, together with the reduced need to treat
drug-related side-effects make
teicoplanin more cost-effective. It is as effective as
vancomycin for most indications, is safe, easy to administer and an important agent for treating Gram-positive
infections. Its role in hospitals is likely to increase if the price of
drug acquisition is kept low.